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Ubiquitin chains serve as a recognition motif for
the proteasome, amultisubunit protease, which
degrades its substrates into polypeptides while
releasing ubiquitin for reuse. Yeast protea-
somes contain two deubiquitinating enzymes,
Ubp6 and Rpn11. Rpn11 promotes protein
breakdown through its degradation-coupled
activity. In contrast, we show here that Ubp6
has the capacity to delay the degradation of
ubiquitinated proteins by the proteasome.
However, delay of degradation by Ubp6 does
not require its catalytic activity, indicating that
Ubp6 has both deubiquitinating activity and
proteasome-inhibitory activity. Delay of degra-
dation by Ubp6 appears to provide a time win-
dow allowing gradual deubiquitination of the
substrate by Ubp6. Rpn11 catalyzes en bloc
chain removal, and Ubp6 interferes with degra-
dation at or upstream of this step, so that deg-
radation delay by Ubp6 is accompanied by
a switch in the mode of ubiquitin chain process-
ing. We propose that Ubp6 regulates both the
nature and magnitude of proteasome activity.
INTRODUCTION
The ubiquitin-proteasome system is themajor pathway for
intracellular protein degradation in eukaryotes. Substrates
of this pathway acquire a covalently linked polyubiquitin
chain through the action of a cascade of ubiquitin activat-
ing and conjugating enzymes. This ubiquitin chain serves
as the recognition motif for a multisubunit protease known
as the proteasome, which processively degrades the sub-
strate into polypeptides while releasing ubiquitin for reuse
(Pickart and Cohen, 2004).The proteasome is an approximately 2.5 MDa protein
complex consisting of at least 33 distinct subunits in
yeast (Pickart and Cohen, 2004). Its proteolytic active
sites are housed at the center of the structure in a barrel-
shaped subcomplex (Groll et al., 1997) known as the core
particle (CP, or 20S complex). At either axial end of the
CP, a second subcomplex known as the regulatory
particle (RP, or 19S complex or PA700) may bind. The
RP comprises two subcomplexes of its own: the base
and the lid (Glickman et al., 1998). The base is proximal
to the CP and contains, among other proteins, six
ATPases that are thought to form a ring structure that
abuts the CP.
The proteasome displays a number of characteristics
unusual for a protease. First, its proteolytic active sites
are sequestered within the hollow cylindrical chamber of
the CP. Providing access to this internal chamber are nar-
row gates at either end of theCP, and gating appears to be
modulated by the Rpt2 subunit of the base (Pickart and
Cohen, 2004). These features presumably serve to pre-
vent the unregulated destruction of intracellular proteins,
and also impose a requirement for substrate unfolding,
as most folded proteins are too large to pass through
the open translocation channel leading to the CP. Protein
unfolding is apparently mediated by the six ATPases of the
base. Multiple ubiquitin receptors have been identified,
some of which are core proteasomal subunits while others
are substoichiometric proteasome-associating factors
(Elsasser and Finley, 2005). At some point after recogni-
tion, the ubiquitin chain is removed from the substrate to
facilitate substrate degradation and to minimize degrada-
tion of ubiquitin. This function is carried out by deubiquiti-
nating enzymes that reside in the proteasome.
In budding yeast S. cerevisiae, at least two deubiquiti-
nating enzymes are thought to contribute to deubiquitina-
tion by the proteasome: Rpn11 and Ubp6 (Leggett et al.,
2002; Verma et al., 2002; Yao and Cohen, 2002; Maytal-
Kivity et al., 2002; Chernova et al., 2003; Guterman and
Glickman, 2004). Rpn11, a metalloprotease, is a core
structural component of the lid. Point mutations in its
metal-coordinating site impair substrate degradation,Cell 127, 99–111, October 6, 2006 ª2006 Elsevier Inc. 99
indicating a positive role for Rpn11 in protein degradation
(Verma et al., 2002; Yao and Cohen, 2002).
The second proteasomal deubiquitinating enzyme,
Ubp6, has been classified as a proteasome-associated
protein, largely on the basis of its ready dissociation
from the proteasome in the presence of high salt concen-
trations (Leggett et al., 2002). Ubp6, a cysteine protease,
is an abundant component of proteasomes (Verma
et al., 2000; Leggett et al., 2002), and in contrast to
Rpn11, Ubp6 associates with the base. An N-terminal
ubiquitin-like domain (Ubl) of Ubp6 mediates this interac-
tion. Binding of Ubp6 to the proteasome activates Ubp6’s
catalytic activity over 300-fold (Leggett et al., 2002), indi-
cating an intimate functional relationship between Ubp6
and the proteasome. However, the precise role of Ubp6
in proteasome function has remained uncertain. Some re-
ports have assigned Ubp6 little or no role in proteasome-
mediated deubiquitination or degradation, while others
have argued that Ubp6, like Rpn11, facilitates protea-
some-mediated degradation.
Here, we describe the first detailed analysis of how
Ubp6 affects the degradation of a physiological substrate
of the proteasome. We report that Ubp6 delays the break-
down of proteins by the proteasome and that a major
component of its inhibitory effect is noncatalytic in nature.
Negative regulation of degradation byUbp6was observed
in vivo and in vitro, and on different test substrates. During
the degradation delay that Ubp6 imposes, substrate deu-
biquitination proceeds on proteasomes, but the mode of
deubiquitination is altered from that seen in the absence
of Ubp6: degradation-linked ‘‘en bloc’’ chain removal by
Rpn11 is replaced by progressive deubiquitination by
Ubp6. Thus, Ubp6 uses catalytic and noncatalytic mech-
anisms to modulate proteasome function, and the coordi-
nated activity of multiple proteasomal deubiquitinating en-
zymes controls substrate fate.
RESULTS
Ubp6 Inhibits the Degradation of Ubiquitinated
Cyclin B
To study the potential role of Ubp6 in proteasome func-
tion, we developed an in vitro system for proteasome-me-
diated degradation of a model substrate. Ubiquitination of
the short-lived cell cycle regulator cyclin B was achieved
via a reaction requiring E1, Ubc4 (E2), immunopurified
APC (E3), ubiquitin, and ATP (Kirkpatrick et al., 2006).
Upon incubation of ubiquitinated cyclin B with protea-
somes purified from ubp6D mutants, we observed that
the rate of cyclin B degradation was much greater than
that of wild-type proteasomes (Figure 1A). Significantly,
the slower degradation of cyclin B exhibited by wild-type
proteasomes was accompanied by progressive removal
of ubiquitin groups from the substrate. We verified the
absence of Ubp6 in proteasomes purified from the
ubp6D strain (Figure 1B), and that the amounts of protea-
some were comparable between the two preparations
(Figure 1C).100 Cell 127, 99–111, October 6, 2006 ª2006 Elsevier Inc.We next sought to determine whether the observed dif-
ference in cyclin B degradation was due specifically to
Ubp6. We examined proteasomes by Coomassie blue
staining (Figure 1D) and native gel electrophoresis (data
not shown) and found no evidence for either an unex-
pected compositional difference or a gross structural ab-
normality in mutant proteasomes (see also Guterman and
Glickman, 2004). Furthermore, the activity of mutant pro-
teasomes against the peptide substrate suc-LLVY-AMC,
which is hydrolyzed in an RP-dependent but ubiquitin-
independent manner, was comparable to wild-type (Fig-
ure 1E), indicating that delay of cyclin B degradation
by Ubp6 was not due to suppression of the core proteo-
lytic activity of the proteasome, nor to closing the gate
into the CP. Finally, when bacterially expressed purified
Ubp6 was added back to proteasomes lacking Ubp6,
we observed a marked delay of cyclin B degradation (Fig-
ure 1F), indicating that Ubp6 itself is the inhibitory compo-
nent of wild-type proteasomes. Inhibition of degradation
by recombinant Ubp6 (Figure 1F) was accompanied by
progressive deubiquitination, as seen with wild-type pro-
teasomes (Figure 1A).
Rpn11 is known to promote deubiquitination and degra-
dation by the proteasome (Verma et al., 2002; Yao andCo-
hen, 2002). To verify that Rpn11 was active in our system,
we treated ubp6D proteasomes with the metal chelator
o-phenanthroline (o-PA), an inhibitor of Rpn11. o-PA
strongly inhibited deubiquitination and degradation of
cyclin B (Figure 1G). In contrast, o-PA treatment had no
effect on LLVY-hydrolysis by proteasomes (data not
shown). Thus, in contrast to Ubp6, Rpn11 promotes cyclin
B degradation.
In Vitro Confirmation of Degradation Delay by Ubp6
Chemical inhibitors of the proteasome were used to con-
firm that the rapid disappearance of cyclin B in the ab-
sence of Ubp6 represents cyclin B degradation by protea-
somes as opposed to a possible unknown component of
our samples. For these experiments, we utilized epoxomi-
cin, an inhibitor of the proteolytic active sites of the CP.
Epoxomicin preferentially targets the chymotrypsin-like
activity of the CP; at high concentrations, such as used
here, epoxomicin can inhibit all three proteolytic sites, al-
though complete proteasome inhibition is generally not
observed (Kisselev et al., 2006). The yield of deubiquiti-
nated cyclin B reaction products from ubp6D protea-
somes after a 10 min incubation was greatly increased
by epoxomicin, verifying that disappearance of cyclin B in-
volved proteasome-mediated degradation (Figure 2A). A
diminished effect of epoxomicin was observed when the
same experiment was carried out using proteasomes con-
taining Ubp6, reflecting a reduced rate of cyclin B break-
down in the absence of epoxomicin (Figure 2A). These
Ubp6-dependent differences could be recapitulated by
endogenous Ubp6 present in wild-type proteasomes
(Figure 2B).
The cyclin B used in our in vitro assay may be linked
through not only lys-48 (K48) of ubiquitin but also K11
Figure 1. Ubp6 Inhibits Degradation of
Ubiquitinated Cyclin B by Purified Yeast
Proteasomes
(A–C) Processing of ub-cyclin B in vitro by wild-
type or ubp6D proteasomes, visualized by im-
munoblot with antibodies to cyclin B1 (A),
Ubp6 (B), or proteasome subunit Rpn5 (C).
(D) Comparison of wild-type and ubp6D pro-
teasomes (10 mg), as determined by SDS-
PAGE followed by Coomassie staining.
(E) Proteasome-dependent hydrolysis of suc-
LLVY-AMC, a ubiquitin-independent fluoro-
genic proteasome substrate. Error bars reflect
standard deviations.
(F) Processing of ub-cyclin B by proteasomes
in the presence of purified recombinant Ubp6.
Asterisk indicates a cyclin B species generated
by residual thrombin activity deriving from re-
combinant Ubp6 purifications. Comparable
Ubp6 add-back results were obtained with
ubp6D proteasomes purified using a CP affinity
tag (data not shown).
(G) O-phenanthroline (o-PA) inhibits cyclin B
degradation by ubp6D proteasomes, implicat-
ing Rpn11’s deubiquitinating activity in this
process. o-PA, dissolved in DMSO, was added
at 10 mM, 10 min prior to cyclin B.and K63 (Kirkpatrick et al., 2006). We previously reported
that K48 of ubiquitin was not required for in vitro degrada-
tion of ub-cyclin B (Kirkpatrick et al., 2006). We extend
those results here with a side-by-side comparison of
wild-type and ubp6D proteasomes; in both cases, protea-
somes deubiquitinate and degrade cyclin B without re-
gard for the presence of K48 ubiquitin linkages in its
attached ubiquitin chains (Figure 2C). Thus, although
K48-linked ubiquitin chains may be the dominant chain
type promoting degradation in vivo, this linkage is not
required for rapid proteasomal degradation in vitro. For
many substrates, the requirement for K48 in protein
degradation may reflect properties of the E3 enzymes
involved in chain synthesis.
Finally, we noticed that for reactions lacking Ubp6, ep-
oxomicin stabilized, in addition to unmodified cyclin B,
a second major species, which is apparently monoubiqui-tinated cyclin B (Figures 2A–2C). These results suggest
that in the absence of Ubp6, while a majority of ub-cyclin
B is fully deubiquitinated by Rpn11 prior to degradation,
a significant fraction is left incompletely deubiquitinated,
and the resulting monoubiquitinated species is apparently
rapidly degraded. In vivo, ubiquitin undergoes accelerated
degradation by the proteasome in the absence of Ubp6
(Leggett et al., 2002; Hanna et al., 2003; Chernova et al.,
2003; Figure 5D). We have proposed that when Ubp6 is
absent, one or more substrate bound ubiquitin groups
are translocated into the CP and degraded along with their
substrate (Leggett et al., 2002), but until now there had
been no biochemical basis to account for accelerated
ubiquitin turnover. We propose that increased turnover
of monoubiquitinated degradative intermediates as sug-
gested by Figure 2may contribute significantly to the rapid
degradation of ubiquitin in vivo in the absence of Ubp6.Cell 127, 99–111, October 6, 2006 ª2006 Elsevier Inc. 101
Figure 2. Inhibition of Cyclin B Degrada-
tion by Epoxomicin
(A) Effect of purified Ubp6 on proteasome-me-
diated ub-cyclin B processing in the presence
or absence of epoxomicin (100 mM). The as-
signment of monoubiquitinated cyclin B is con-
sistent with a previous study (Kirkpatrick et al.,
2006).
(B and C) Processing of ub-cyclin B by wild-
type and ubp6D proteasomes in the presence
or absence of epoxomicin. Ub-cyclin B was
synthesized with wild-type or K48R ubiquitin,
as indicated.Ubp6 Reduces Degradation Rates In Vivo
Our in vitro data predict accelerated degradation of at
least some proteasomal substrates in vivo in the absence
of Ubp6. To test this idea, we used chromosomal integra-
tion to render the biosynthetic enzymes Trp1 and Ura3 un-
stable by appending an N-terminal segment that directs
these proteins to the N-end rule pathway for degradation
(Varshavsky, 2005). Accordingly, growth of such strains in
the absence of the relevant metabolite should reflect the
rate of degradation of the respective reporter protein.
Strains harboring proteolytic defects should stabilize the
reporters, and thus display increased growth relative to
wild-type. Ubr1, the E3 of the N-end rule pathway, gov-
erns ubiquitination of the reporter proteins. As expected,
the ubr1D mutant displays a strong growth advantage102 Cell 127, 99–111, October 6, 2006 ª2006 Elsevier Inc.over wild-type when cultured onmedia lacking tryptophan
(Figure 3A) or uracil (data not shown).
Although such assays have typically been used to char-
acterize degradation defects, we reasoned that if signifi-
cant growth were detectable in wild-type strains, the
assay could also be used to identify mutants with in-
creased degradation rates. Indeed, when ubp6Dmutants
were tested, they displayed a dramatic growth defect
relative to wild-type (Figure 3A), consistent with a protea-
some hypermorphic effect. Additionally, a ubr1D ubp6D
double mutant retained the robust growth phenotype of
the ubr1D single mutant, ruling out a protein synthesis
defect as the cause of the poor growth of the ubp6D strain
(data not shown). Ura3 reporter strains that are wild-
type for UBP6 showed no growth in the absence of uracil,
Figure 3. Deletion of the UBP6 Gene Ac-
celerates Degradation of Proteasome
Substrates In Vivo
(A) Growth of wild-type (SYT303), ubp6D
(SJH170), and ubr1D (SYT304) yeast strains
on media containing or lacking tryptophan, as
indicated.
(B) Cycloheximide-chase reactions examining
turnover of the Ura3 and Trp1 reporter proteins
in wild-type (SYT318), ubp6D (SJH126), and
ubr1D (SYT342) strains. Reactions were visual-
ized with immunoblots using antibodies
against the HA-epitope or proteasome subunit,
Rpn5, as indicated. Far right, shorter exposure
of the ubr1D lanes.
(C) Cycloheximide chase analysis of Gcn4 turn-
over in wild-type and ubp6D strains. Logarith-
mically growing cultures were treated with
cycloheximide (20 mg/ml), and aliquots were
taken at the indicated times. Cells were imme-
diately resuspended in 13 SDS-sample buffer
(LLB), and endogenous Gcn4 was detected
by immunoblot using anti-Gcn4 antibody.
Rpn5 (lower panel) served as a loading control.precluding the corresponding comparison (data not
shown).
The results from Figure 3A suggested that the reporter
proteins were turned over more rapidly in the ubp6D
strain. To test this idea directly, we conducted cyclohexi-
mide-chase analyses in strains harboring both reporter
constructs. In the wild-type strain we observed rapid deg-
radation of both reporters, with half-lives on the order of
several minutes (Figure 3B). In the ubr1Dmutant, both re-
porters were highly stabilized (Figure 3B). In contrast, in
the ubp6D mutant, the Ura3 reporter disappeared more
rapidly than in wild-type, and showed a decreased
steady-state level (Figure 3B). Steady-state levels of the
Trp1 reporter were also depressed in the ubp6D mutant
(Figure 3B), falling below the level of detection. The level
of a control protein, proteasome subunit Rpn5, remained
constant throughout, indicating the specificity of these
effects.
In addition to N-end Rule substrates, we examined the
short-lived transcription factor Gcn4, expressed from its
own promoter in untagged form. Again, we observed ac-
celerated degradation in the ubp6D mutant, with a con-
comitant decrease in steady-state levels (Figure 3C).
Thus, multiple short-lived proteins are turned over more
rapidly in vivo in the absence of Ubp6.
The Deubiquitinating Activity of Ubp6 Is Not
Required for Degradation Delay
To determine which functional elements of Ubp6 are re-
quired for degradation delay, we generated and tested
a number of Ubp6 mutants (Figure 4A). An N-terminal
ubiquitin-like domain (Ubl) is necessary and sufficient to
mediate binding to the proteasome, but is not requiredfor the catalytic activity of purified Ubp6 (Leggett et al.,
2002). Deletion of the Ubl domain rendered Ubp6 noninhi-
bitory in the cyclin B degradation assay (Figure 4B), sug-
gesting that Ubp6must be bound to the proteasome to in-
hibit cyclin B degradation. The Ubl domain by itself also
had no effect on cyclin B degradation (Figure 4E). Thus,
the ability of Ubp6 to delay degradation of cyclin B jointly
requires the Ubl and C-terminal domains of the protein.
Although efficient degradation of ubiquitin conjugates
by the proteasome is thought to require removal of ubiqui-
tin groups prior to translocation of the substrate into the
CP, premature removal of ubiquitin chains could result in
dissociation of the substrate and antagonize its degrada-
tion (Lam et al., 1997). Such a scenario could provide
a straightforwardmeans bywhich deubiquitinating activity
at the proteasome could inhibit protein breakdown. The
joint requirements of the Ubl and C-terminal domains of
Ubp6 for inhibiting cyclin B degradation are consistent
with this view. However, a catalytically inactive point
mutant of Ubp6 (Ubp6-C118A) proved competent for deg-
radation delay (Figure 4B). Thus, Ubp6 does not prevent
cyclin B degradation simply through premature deubiqui-
tination. To substantiate this conclusion, we verified that
Ubp6-C118A is completely devoid of deubiquitinating ac-
tivity against the model substrate Ub-AMC (Figure S1 in
the Supplemental Data available with this article online),
but retains wild-type binding affinities for the proteasome
(data not shown; Chernova et al., 2003).
As an alternate approach to assay noncatalytic inhibi-
tion, we utilized ubiquitin-vinyl sulfone (Ub-VS), an irre-
versible active site inhibitor of Ubp6. Although it com-
pletely eliminated catalytic activity of wild-type Ubp6 as
measured by Ub-AMC hydrolysis, inhibition of cyclin BCell 127, 99–111, October 6, 2006 ª2006 Elsevier Inc. 103
Figure 4. A Noncatalytic Function of Ubp6 in Proteasome Inhibition
(A) Schematic of the various Ubp6 mutants. MBP, maltose binding protein. (B and E) Ub-cyclin B processing by ubp6D proteasomes, in the presence
or absence of the indicated Ubp6 species. Inhibition of degradation by Ubp6-C118A was also observed using proteasomes purified via a CP affinity
tag (data not shown). (C) A comparison of the extent of proteasome inhibition bywild-typeUbp6 andUbp6-C118A by quantitativemass spectrometry.
Upper panels, immunoblots using anti-cyclin B, -Ubp6, and -Rpn12 antibodies as indicated. Lower panel, quantitation results. Error bars represent
the standard deviation of two independent quantitations. (D) Ubp6 fails to deubiquitinate cyclin B when proteasomes are absent. (F) Electrophoretic
mobility shift of proteasome bound to ubiquitinated Cdc34. Proteasomes were visualized using the fluorogenic substrate suc-LLVY-AMC.degradation by Ubp6 persisted (Figure S2). This finding
also indicates that degradation delay by Ubp6-C118A
cannot be attributed to nonproductive ubiquitin chain
binding at the active site of the mutant enzyme. Indeed
the large excess of substrate over Ubp6 (see Experimental
Procedures) is inconsistent with a model in which Ubp6104 Cell 127, 99–111, October 6, 2006 ª2006 Elsevier Inc.delays degradation by sequestering substrate. Taken to-
gether, these data show that Ubp6 has two distinct func-
tions, one catalytic and one noncatalytic. Although these
functions are distinct, each requires both the Ubl domain
and the C-terminal domain. We suggest that the Ubl
domain serves in both cases to target Ubp6 to the
proteasome, and that both functions are obligatorily exe-
cuted on the proteasome.
Although Ubp6-C118A was, like wild-type Ubp6, com-
petent to delay cyclin B degradation, the fate of cyclin B
over the time course of the incubation was affected by
the loss of deubiquitinating activity in the mutant enzyme.
When wild-type Ubp6 was used for reconstitution, a
progressive reduction in electrophoretic mobility of cyclin
B immunoreactive material was seen, whereas these
mobility shifts were not observed with Ubp6-C118A
(Figure 4B). These data imply that the mobility shifts
represent trimming of ubiquitin or ubiquitin chains bound
to cyclin B, and that the trimming reaction ismediated pre-
dominantly or exclusively by the deubiquitinating activity
of Ubp6.
To quantify the extent of degradation delay by Ubp6, we
utilized a recently developed method of quantitative mass
spectrometry (Kirkpatrick et al., 2006). After a 20min incu-
bation, approximately half of the total cyclin B was de-
graded by ubp6D proteasomes (Figure 4C). High molecu-
lar weight ubiquitin-cyclin B conjugates were almost
completely eliminated by this time, but degradation would
not be expected to go to completion because a fraction of
the input cyclin B had not been ubiquitinated. Addition of
purified Ubp6 or Ubp6-C118A resulted in approximately
70% inhibition of degradation at this time point
(Figure 4C), which may underestimate the Ubp6 inhibitory
effect, since the course of degradation seemed to be
nearing completion in the control sample.
Ubp6 Prevents Rpn11-Dependent Ubiquitin Chain
Removal
The linkage of Rpn11 activity to substrate degradation can
be abrogated by proteasome inhibitors, presumably be-
cause they act downstream of Rpn11 (Verma et al.,
2002; Yao and Cohen, 2002). Thus, to visualize the activity
of Rpn11 on cyclin B, we used proteasome inhibitor
treated ubp6D proteasomes, as in Figure 2. This figure
showed, as described above, that the effect of Ubp6 on
cyclin B disappearance is mediated by an altered rate of
proteasome-mediated degradation. However, since the
results of Figure 4 indicate that the deubiquitination seen
during degradation delay is mediated by Ubp6, and not
by Rpn11, it appears that Ubp6 inhibits the proteasome
at a point in the reaction pathway such that Rpn11-medi-
ated chain removal is prevented.
In the presence of epoxomicin, Rpn11 can be seen to
cleave substrate-linked chains at or near their base, re-
sulting in the production of a prominent band of unmodi-
fied substrate protein (Verma et al., 2002; Yao and Cohen,
2002; Figure 2). Whenwe compared the reaction products
from wild-type and ubp6D proteasomes pretreated with
epoxomicin, we observed in ubp6D reactions a greater
amount of unmodified cyclin B, reflecting substrate deubi-
quitinated but not degraded by the proteasome (Figures
2A–2C). In the presence of Ubp6, a lesser amount of un-
modified cyclin B was stabilized by the inhibitor; instead,
the majority of the cyclin B remained as higher molecularweight species, most likely reflecting partial deubiquitina-
tion. The increased yield of unmodified cyclin B in the
presence of ubp6D proteasomes as compared to wild-
type indicates that Rpn11-dependent chain removal
from substrate is suppressed in the presence of Ubp6.
However, it remains unclear whether Ubp6 directly inhibits
Rpn11 or some other activity that may function upstream
of Rpn11.
Evidence that Interference with Substrate-
Proteasome Interaction Cannot Explain
Proteasome Inhibition by Ubp6
One potential explanation for the degradation-inhibitory
effect of Ubp6 is that binding of Ubp6 to the proteasome
is competitive with that of substrate. Several lines of evi-
dence indicate that Ubp6 does not inhibit the proteasome
by thismechanism. As seen in Figure 4B, the deubiquitina-
tion of cyclin B that occurs in the complete reaction
mixture is mediated by Ubp6. However, when Ubp6 is
incubated in the presence of cyclin B, but without protea-
somes, no deubiquitination of cyclin B is observed
(Figure 4D). Thus, Ubp6 requires the proteasome for its
deubiquitinating activity on cyclin B. These data suggest
that both Ubp6 and cyclin B are bound to proteasomes
so long as cyclin B deubiquitination proceeds, which
can be an extended period, since the deubiquitination
reaction is progressive over the time courses shown in
Figure 4.
Ubp6 could conceivably inhibit cyclin B degradation via
a substrate-titration mechanism. However, we were un-
able to observe direct interaction between Ubp6 and ub-
cyclin B using a GST pull down assay that sensitively de-
tects binding of ub-cyclin B to ubiquitin receptors such as
Rpn10, Rad23, and Dsk2 (Figure S3 and Kirkpatrick et al.,
2006). These findings are consistent with a previous report
that the KM of Ubp6 for ubiquitin ethyl ester is so high as to
be unmeasurable (Chernova et al., 2003).
Ubp6 is large enough, at 57 kDa, that its presence on
the proteasome could conceivably impede binding of sub-
strates or substrate receptors. Also, the pathway of sub-
strate translocation through the proteasome might be
blocked by nonspecific steric interference. To address
this possibility we constructed a fusion protein in which
the Ubl of Ubp6 was fused N-terminally to the maltose
binding protein of E. coli (Figure 4A), resulting in a fusion
protein of nearly the same size as Ubp6. Despite binding
the proteasome (data not shown), this construct, as for
the Ubl alone, failed to delay cyclin B degradation
(Figure 4E).
Finally, we directly evaluated the effect of Ubp6 on con-
jugate binding to the proteasome by using autoubiquiti-
nated Cdc34, a substrate that binds proteasomes but is
notdegraded (Elsasseret al., 2004).Usinganactivity-based
electrophoretic mobility shift assay (Elsasser et al., 2004),
we observed comparable conjugate binding in the pres-
ence and absence of Ubp6-C118A (Figure 4F). Conjugate
binding was observed in the presence of wild-type
Ubp6, but was also accompanied by deubiquitination, asCell 127, 99–111, October 6, 2006 ª2006 Elsevier Inc. 105
Figure 5. In Vivo Differentiation of ubp6D and ubp6-C118A Mutants
(A and B) Growth of wild-type (SJH30), wild-type overexpressing ubiquitin (SJH34), ubp6D (SJH31), and ubp6D overexpressing ubiquitin
(SJH35) yeast strains on selective plates containing copper sulfate (100 mM) in the presence or absence of canavanine (1.5 mg/ml) or rapamycin
(200 ng/ml), and grown at 30C for 3–7 days.
(C) Growth of wild-type (SJH152), ubp6D (SJH153), ubp6D expressingwild-typeUbp6 (SJH154), and ubp6D expressingUbp6-C118A (SJH155) yeast
strains on selective plates containing no drug, canavanine (1.5 mg/ml), or rapamycin (200 ng/ml) as indicated, and grown at 30C for 3-7 days. For
SJH154 and SJH155, duplicates represent two independent transformants.
(D) Cycloheximide-chase analyses of free ubiquitin turnover were conducted in wild-type (SJH120), ubp6D overexpressing wild-type Ubp6 (SJH20),
and ubp6D overexpressing Ubp6-C118A (SJH22) strains, as indicated.
(E) Growth of wild-type (SJH171), ubp6D (SJH172), ubp6D expressingwild-type Ubp6 (SJH173), and ubp6D expressing Ubp6-C118A (SJH174) yeast
strains on selective media containing or lacking tryptophan, as indicated.106 Cell 127, 99–111, October 6, 2006 ª2006 Elsevier Inc.
Figure 6. Degradation Independence
and Evolutionary Conservation of Ubp6
Function
(A and B) Processing of ub-cyclin B by RP
(ubp6D) in the presence or absence of purified
Ubp6. Reactions were visualized by immuno-
blotting with anti-cyclin B antibody or anti-
ubiquitin antibody, as indicated.
(C) Effect of Ubp6 or its human homolog,
Usp14, on the processing of ub-cyclin B by
yeast ubp6D proteasomes.determined by immunoblot (S.E., J.H., and D.F., unpub-
lished data). Taken together, the data of Figures 4E and
4F indicate that noncatalytic proteasome inhibition by
Ubp6 is unlikely to be achieved through simple sterically
basedmechanisms but instead may involve specific func-
tionalities within the C-terminal domain of Ubp6.
Noncatalytic Effects of Ubp6 In Vivo
We next sought in vivo evidence for the nonequivalence of
the null and catalytic point mutants of Ubp6. A number of
ubp6D phenotypes that can be suppressed by ubiquitin
overexpression have been described (Chernova et al.,
2003; Hanna et al., 2003), including hypersensitivity to
the amino acid analog canavanine (Figure 5A) and to sev-
eral translational inhibitors. Intriguingly, we have found
that not all ubp6D phenotypes are ubiquitin dependent.
For instance, we observed a strong resistance of ubp6D
to rapamycin, an inhibitor of the TOR pathway (Wulls-
chleger et al., 2006), which globally regulates the state of
the yeast cell accord to nutritional conditions. The rapa-
mycin resistance of ubp6Dwas not suppressed by ubiqui-
tin overexpression (Figure 5B). This result suggests func-
tions of Ubp6 outside of ubiquitin regeneration, possibly
reflecting noncatalytic functions of Ubp6. To test this
hypothesis, we expressed wild-type Ubp6 and Ubp6-
C118A from its endogenous promoter in a ubp6D strain.
Wild-type Ubp6 complemented both the canavanine and
rapamycin phenotypes (Figure 5C). As expected, expres-
sion of Ubp6-C118A failed to rescue canavanine hyper-
sensitivity (Figure 5C; Leggett et al., 2002) but in contrast
largely complemented rapamycin resistance (Figure 5C).
Ubp6-ublD recapitulated the null phenotype, suggesting
that the rapamycin-related noncatalytic functions ofUbp6 occur on the proteasome (Figure S4). These results
provide in vivo evidence that the ubp6D and ubp6-C118A
mutants are not equivalent and support the hypothesis
that Ubp6 performs noncatalytic functions, as observed
in vitro.
In the absence of Ubp6, free ubiquitin is rapidly turned
over (Figure 5D; Leggett et al., 2002). The failure of
Ubp6-C118A to complement ubiquitin-dependent pheno-
types such as canavanine hypersensitivity suggested
aberrant ubiquitin turnover in ubp6-C118Amutants. Over-
expression of wild-type Ubp6, but not Ubp6-C118A,
restored ubiquitin stability (Figure 5D), indicating that the
ubiquitin recycling function of Ubp6 is catalytic in nature.
These results provide a mechanistic basis for understand-
ing why the Ubp6-C118A mutation affects ubiquitin-de-
pendent but not ubiquitin-independent phenotypes, and
indicate that the noncatalytic function of Ubp6 is distinct
from its function in ubiquitin homeostasis.
Finally, we utilized the Ub-K-Trp1 substrate described
in Figure 3 to test whether noncatalytic inhibition of degra-
dation by Ubp6 was also operational in vivo. As shown in
Figure 5E, expression of Ubp6-C118A restored growth on
media lacking tryptophan, indicating stabilization of the
Ub-K-Trp1 protein. Importantly, wild-type Ubp6 was
more effective in stabilizing Ub-K-Trp1 than was Ubp6-
C118A. Thus both catalytic and noncatalytic features of
Ubp6 appear to mediate proteasome inhibition in vivo
(see Discussion).
In summary, the results of Figure 5 show that Ubp6 has
a noncatalytic inhibitory effect on protein breakdown
in vivo and that the biology of the cell is sensitive to a non-
catalytic function of Ubp6 as shown for example by the
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Protein turnover effects were observed without overex-
pression of Ubp6, indicating that significant proteasome
inhibition is in effect under normal growth conditions in
wild-type cells.
Deubiquitination of Cyclin B by Ubp6
Rpn11 has been reported to function in the context of the
26S proteasome, but not in the context of the RP or the lid
(Verma et al., 2002), although there have been differing re-
ports (Yao and Cohen, 2002; Guterman and Glickman,
2004). In our assay, RP purified from a ubp6Dmutant pro-
duced no detectable deubiquitination of cyclin B conju-
gates (Figure 6A). In contrast, addition of purified Ubp6
to RP resulted in progressive deubiquitination, although
to a lesser extent than with 26S proteasomes (Figure 6A).
Addition of Ubp6-C118A to RP had no effect on substrate
processing (Figure S5), further verifying that deubiquitina-
tion seen with wild-type Ubp6 reflects the catalytic activity
of Ubp6 itself. The immunoreactivity at the position of un-
modified cyclin B before and after Ubp6 processing was
of approximately equal intensity. Thus, although it can pro-
gressively remove ubiquitin groups from cyclin B, Ubp6
produces unmodified cyclin B less readily than Rpn11.
We examined the fate of ubiquitin in the presence of RP-
bound Ubp6 by anti-ubiquitin immunoblots. We found
a decrease in the overall size and intensity of the high mo-
lecular weight material, consistent with the data from
Figure 6A, but also observed reaction products comigrat-
ing with diubiquitin, triubiquitin, and larger ubiquitin poly-
mers (Figure 6B). Presumably, monoubiquitin was also
generated, although this was difficult to discern because
of the high levels of free ubiquitin present in the reactions.
In reactions utilizing lower amounts of substrate, Ubp6-
dependent generation of free ubiquitin was readily ob-
served (Figure S5). These results suggest a preference
of Ubp6 for the distal end of ubiquitin chains (see also
Hu et al., 2005); alternatively, Ubp6 may cleave proximally
to remove monoubiquitin and small ubiquitin chains. A
third deubiquitinating enzyme, Uch37, which is absent
from budding yeast, has been reported to possess a dis-
tal-end-directed activity on the proteasome (Lam et al.,
1997). However, whereas Uch37 appears to remove ubiq-
uitins one at a time, progressive deubiquitination by Ubp6
is not limited to the trimming of single ubiquitins.
The In Vitro Functions of Ubp6 are Evolutionarily
Conserved
Ubp6 and its human homolog Usp14 share 32% se-
quence identity (Chernova et al., 2003). Several features
of Ubp6, including proteasome binding and activation by
proteasome binding, are shared by Usp14 (Borodovsky
et al., 2001). Indeed, overexpressed Usp14 complements
several in vivo phenotypes of ubp6D in yeast (Chernova
et al., 2003). We therefore tested whether purified re-
combinant Usp14 could substitute for Ubp6 in the cyclin
B degradation assay, using ubp6D proteasomes from
yeast. Usp14 largely recapitulated the effects of Ubp6
(Figure 6C): ub-cyclin B was not only stabilized against108 Cell 127, 99–111, October 6, 2006 ª2006 Elsevier Inc.degradation by Usp14, but progressively deubiquitinated
to lower molecular weight forms. Usp14 is slightly less
efficient than Ubp6 in this assay, perhaps reflecting a
decreased affinity of Usp14 for yeast proteasomes com-
pared to Ubp6. These results, in combination with the
reported in vivo complementation of ubp6D by Usp14, in-
dicate that the observed effects of Ubp6 in our reconsti-
tuted system are likely to represent major functions of
Ubp6 in vivo.
DISCUSSION
A Proteasome Component that Delays Proteasome
Action
Proteasomes regenerate ubiquitin by separating it from
substrate prior to substrate degradation. Interestingly,
the proteasomes of most eukaryotes are associated with
three deubiquitinating enzymes. Indeed, the mammalian
proteasome has asmany distinct active sites for deubiqui-
tination as it has proteolytic active sites for substrate hy-
drolysis. It is unclear why so many activities are required
for deubiquitination at the proteasome, how they are re-
lated to one another, how their function is coupled to sub-
strate degradation, and to what extent deubiquitination
may antagonize degradation by removal of the substrate’s
targeting signal.
The activity of one proteasomal deubiquitinating en-
zyme, Rpn11, is coupled to and facilitates degradation
(Verma et al., 2002; Yao and Cohen, 2002). Here, we re-
port that another proteasomal deubiquitinating enzyme,
Ubp6, has the opposing capacity to delay degradation.
Studies with Uch37 have shown that a proteasomal deu-
biquitinating enzyme can potentially antagonize degrada-
tion by premature deubiquitination (Lam et al., 1997).
However, Ubp6 antagonizes degradation by a novel
mechanism that does not require deubiquitination of the
degradative substrate: it appears to inhibit the proteasome
directly. Proteasomes operate on ub-cyclin B in vitro with
substantially reduced efficiency when they are bound to
Ubp6, and Ubp6 shows a comparable in vivo effect in
reducing flux of at least some specific substrates through
the proteasome. These negative effects are seen under
standard growth conditions, where Ubp6 is a major pro-
teasome component.
Substrate Deubiquitination by Rpn11 is Negatively
Controlled by Ubp6
One aspect of Ubp6’s inhibitory action is to prevent en
bloc deubiquitination of the substrate by Rpn11 (Figure 2).
During the degradation delay imposed by Ubp6, its own
deubiquitinating activity is operational, as can be seen in
a gradual reduction in the number of substrate bound
ubiquitin groups (Figures 4 and 6). Thus, Ubp6 appears
to delay the degradation of and progressively deubiquiti-
nate the same substrate. In this way, the mode of sub-
strate deubiquitination is significantly altered from that
seen in the absence of Ubp6. These results show that
the proteasome has distinct modes of deubiquitination,
and that the en bloc mode is subject to negative control,
principally by a noncatalytic function of Ubp6.
If Ubp6 were to inhibit degradation downstream of
Rpn11, the substrate would lack ubiquitin modification
during degradation delay. In this scenario, release from
Ubp6-mediated degradation delay might be unproduc-
tive, as substrates lacking a ubiquitin modification would
presumably dissociate from the proteasome rather than
be degraded. Thus, inhibition of the proteasome by
Ubp6 appears to delay the decision of whether the sub-
strate will be degraded, and during the delay, attrition of
substrate bound ubiquitin on the substrate proceeds
gradually through the activity of Ubp6. The length of time
allowed for delay of degradation may be an important pa-
rameter. During this time period, shortening of ubiquitin
chains beyond a critical length may lead to dissociation
of the substrate from the proteasome. This model implies
that the presence of two distinct activities in Ubp6, cata-
lytic and noncatalytic in nature, is unlikely to be fortuitous.
An interesting possibility is that the catalytic activity of
Ubp6 should also inhibit degradation, and moreover it
may do so in a manner that is strongly dependent on the
duration of noncatalytic inhibition. Our in vivo data
(Figure 5E) provide initial support for this model, although
further work will be required. We have so far not observed
catalytically based inhibition in vitro. However, it may be
that the extent of cyclin B ubiquitination achieved in our
in vitro reaction is high enough that limited deubiquitina-
tion does not compromise binding of the conjugate to
the proteasome, while substrates bearing shorter chains,
or exposed to longer time courses, would display such
an inhibitory capacity of Ubp6 more clearly.
The Mechanism of Degradation Delay by Ubp6
This study shows that a deubiquitinating enzyme can uti-
lize noncatalytic functions to modulate the activity of an-
other protein—in this case, the proteasome. As there
seems to be no interference with substrate binding on
the part of Ubp6, an interaction between Ubp6 and the
proteasome most likely mediates degradation delay.
Ubp6 is tethered to the proteasome through its Ubl do-
main, which binds subunit Rpn1 of the base (Leggett
et al., 2002; Stone et al., 2004). However, proteasome
binding by the Ubl domain itself has no inhibitory effect
(Figure 4E). Indeed, both the Ubl and C-terminal domains
are required for inhibition. A simple model is that the Ubl
domain serves only a proteasome-tethering role and that
the C-terminal domain contains the specific sequence in-
formation for inhibition. Crystal structures of Ubp6 and its
mammalian homolog, USP14, indicate several regions
within the C-terminal domain of Ubp6, including a notable
surface-exposed alpha helix, that are not conserved with
the unrelated deubiquitinating enzyme HAUSP, and are
unlikely to contribute to enzymatic activity (Hu et al.,
2005). In contrast, these regions are highly conserved
among Ubp6 homologs (J.H. and D.F., unpublished
data), and it may be that one of these regions mediates
the noncatalytic activity of the protein.Wehave largely ruled out roles for Ubp6 in substrate tar-
geting (Figures 4E and 4F), gate opening (Figure 1E), mod-
ulation of CP active sites (Figure 1E), as well as modulation
of overall proteasomal ATPase activity (data not shown).
Interestingly, our previous studies suggested that the C-
terminal domain of Ubp6 has lid binding activity (Leggett
et al., 2002); this interaction might mediate degradation
delay. This speculative model, if confirmed, would be par-
ticularly interesting since the lid is required for full activa-
tion of Ubp6 upon complex formationwith the proteasome
(Leggett et al., 2002). Thus, the same Ubp6-lid binding
event could conceivably inhibit the proteasome and assist
in the activation of Ubp6. Since Rpn11 is a component of
the lid, the lid interaction model also suggests that Ubp6
may delay degradation by directly inhibiting Rpn11 rather
than an unknown step upstream of Rpn11.
Proteasome inhibition by Ubp6 is not complete. Al-
though this is not surprising—complete inhibition of the
proteasome would be detrimental—the mechanism by
which inhibition is relieved is unclear. It is also unclear
whether release of the proteasome from Ubp6-mediated
degradation delay is itself a regulated step. Since Ubp6
is not an integral subunit of the proteasome, the fraction
of proteasomes associated with Ubp6 can in principle
be freely varied, so the overall extent of proteasome inhi-
bition could be regulated through simple means such as
altering cellular Ubp6 levels, or alternatively via posttrans-
lational modulation of Ubp6 activity.
Ubp6 and the Selectivity of the Proteasome
An outstanding question concerns the generality of the
degradation-inhibitory effect of Ubp6. Interestingly, the in-
hibitory effects are not restricted to poor degradative sub-
strates. To determine whether degradation delay by Ubp6
is to any extent substrate-specific, it will be of interest to
determine the effect of ubp6mutations on the rates of deg-
radation of a wider variety of substrates. If substrates are
affected to very different degrees by Ubp6, it would sug-
gest that Ubp6 may slow degradation rates to enhance
the selectivity of protein degradation by the proteasome.
Studies of nucleotide polymerases (Joyce and Benkovic,
2004) as well as protein synthesis (Cochella and Green,
2005) have shown that that speed and fidelity cannot be
optimized simultaneously, but are competing functional
criteria. The definition of fidelity for a protease cannot be
as clear as for a polymerase, but fidelity may bemore eas-
ily defined from the standpoint of the fate of ubiquitin
groups than of substrates. Ubp6 clearly enhances ubiqui-
tin sparing by the proteasome both in vitro and in vivo, and
thus enhances a significant aspect of its fidelity.
Several previous studies have reported Ubp6 to play
positive roles in the degradation of specific proteins (Leg-
gett et al., 2002; Miura and Abe, 2004), in contrast to the
present work. These observations do not appear to reflect
limited scope of the proteasome-inhibitory effect de-
scribed here, but rather the critical role of Ubp6 in main-
taining cellular ubiquitin levels, and the importance of ubiq-
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particular proteins. For example, yeast Tat2 can be de-
graded in a UBP6-dependent manner, but Tat2 is a mem-
brane protein and its degradation appears to proceed
through the vacuole rather than the proteasome. In addi-
tion, Tat2 degradation is sensitive to mutations in other
genes that affect cellular ubiquitin levels (Miura and Abe,
2004). The other known example is ubiquitin-proline-b-ga-
lactosidase (Leggett et al., 2002), whose degradation is
highly sensitive to ubiquitin levels (Johnson et al., 1995).
Implications for Protein Turnover in Mammals
The substrate-stabilizing effects of ubiquitin deficiency
could potentially obscure the destabilizing effects of re-
lease from proteasome inhibition in the ubp6D mutant. It
will be particularly interesting to uncouple these opposing
effects in ataxiamice, whose biochemical basis is loss-of-
function mutation in Ubp6/Usp14. These mice display
a severe neurologic phenotype culminating in widespread
paralysis and premature death (Wilson et al., 2002).
Whether these phenotypes are a result of ubiquitin deple-
tion or enhanced proteasomal degradation, or both, and
whether either of these cellular phenomena may have rel-
evance for human neurologic or neurodegenerative dis-
eases remains an intriguing open question.
In recent years, pharmacologic inhibition of the protea-
some’s proteolytic active sites has emerged as an effec-
tive anti-cancer treatment in such clinical contexts as mul-
tiple myeloma (Adams, 2004). The efficacy of such drugs
may reflect an increased requirement for proteasome
function in some cancer cells. On the other hand, there
may exist clinical scenarios in which a deficit of protea-
some function contributes significantly to pathophysiol-
ogy. Deficient proteasome function has been suggested,
for example, to underlie various proteinopathies and neu-
rodegenerative diseases (Goldberg, 2003). For diseases
characterized by proteasome deficiency, drugs that inhibit
a broadly acting proteasome inhibitor such as Ubp6 may
provide an effective therapy.
EXPERIMENTAL PROCEDURES
Yeast Strains
Yeast strains and plasmids are given in Table S1. General methods for
yeast are described in the supplement.
Recombinant Proteins
See Table S1. Recombinant proteins were expressed as GST-fusion
proteins, purified by glutathione-Sepharose affinity chromatography,
and eluted by thrombin cleavage, as described (Leggett et al., 2002).
Eluates were treated with benzamidine or benzamidine-Sepharose
to inactivate thrombin.
Ubp6-C118Amutants were generated by site-directed mutagenesis
using the Quikchange system (Stratagene) and verified by DNA se-
quencing. The Ubl-MBP construct was generated by fusing the first
83 codons from UBP6 to the 50 end of the complete coding sequence
of the maltose binding protein from E. coli.
Proteasome Purification
A previously described procedure for purification of the proteasome
(Leggett et al., 2002) was modified by adding 1 mM ATP and 5 mM110 Cell 127, 99–111, October 6, 2006 ª2006 Elsevier Inc.MgCl2 to all purification buffers and by washing resins with 100 bed
volume of buffer containing 50mMNaCl, as opposed to 50 bed volume
of buffer containing 100 mM NaCl. RP was purified in the presence of
ATP and MgCl2 as described (Leggett et al., 2002).
In Vitro Deubiquitination/Degradation Assays
Proteasomes (135 nM) were incubated with ub-cyclin B in the pres-
ence of 1 mM ATP and buffer (50 mM Tris [pH 7.5], 1 mM EDTA,
5 mM MgCl2) for the indicated times. Reactions were terminated by
the addition of 53 SDS Laemmli loading buffer (Leggett et al., 2002)
and boiled for 5 min. Where indicated, recombinant, purified Ubp6 or
Usp14 species (540 nM) were preincubated with proteasomes for
5 min prior to the reaction. Ubl and Ubl-MBP species were used at
1.35 mM to compensate for lower affinity of these species for protea-
some binding compared to full-length Ubp6 species (Leggett et al.,
2002; data not shown). Epoxomicin (100 mM) was used to inhibit pro-
teolytic activity of proteasomes. Unless otherwise noted, immunoblots
were visualized with anti-cyclin B1 polyclonal antibodies. Polyclonal
antibodies recognizing Ubp6, Rpn5, Rpn12, and ubiquitin were used
as indicated. Ub-cyclin B was added in molar excess over protea-
some, generally on the order of 25-fold, except for Figures 4C, 6A,
and 6B, where the substrate: enzyme ratio was increased by a factor
of five.
In the experiments of Figures 1, 4 (except 4C), and 6C, time points
were sampled after the preparation of a single reaction mixture. The
zero time points therefore reflect a lag which represents the amount
of time required to sample the first time point after having prepared
the reaction mixture. This time lag was consistent between samples,
and less than 20 seconds. However, the activity of Ubp6 is rapid
enough to reduce cyclin B ubiquitination by time zero. In the experi-
ments of Figures 2, 4C, and 6 (except 6C), each time point was carried
out as an independent reaction. The zero time points were prepared in
the presence of 53 LLB, and accordingly, no processing could occur
before time zero.
In Vivo Degradation Assays
For plating assays, 3-fold serial dilutions of yeast cultures grown in
YPD were spotted onto plates containing or lacking tryptophan. For
cycloheximide chase assays, exponential cultures in YPD supple-
mented with 100 mM copper sulfate (to further induce expression of
the reporter proteins) were normalized to an equivalent cell density
and cycloheximide (50 mg/mL unless otherwise noted) was added. At
the indicated time points, an aliquot of each culture was removed,
and cells were pelleted and resuspended in 13 LLB. Samples were im-
mediately frozen on dry ice for the remainder of the time course, and
subsequently boiled for 5 min. Visualization was by immunoblotting
with anti-HA antibody (12CA5) or anti-Rpn5 antibody, as indicated.
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures,
Supplemental References, one table, and five figures and can be found
with this article online at http://www.cell.com/cgi/content/full/127/1/
99/DC1/.
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